oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Preserved beta-Cell Function in Type 1 Diabetes by Mesenchymal Stromal Cells
Uppsala Univ, Dept Med Cell Biol, Uppsala, Sweden.;Uppsala Univ, Dept Med Sci, Uppsala, Sweden..
Orebro University Hospital. Internal Med, Orebro.
Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden..
Karolinska Inst, Dept Lab Med, Stockholm, Sweden..
2015 (English)In: Diabetes, ISSN 0012-1797, E-ISSN 1939-327X, Vol. 64, no 2, 587-592 p.Article in journal (Refereed) Published
Abstract [en]

The retention of endogenous insulin secretion in type 1 diabetes is an attractive clinical goal, which opens possibilities for long-term restoration of glucose metabolism. Mesenchymal stromal cells (MSCs) constitute, based on animal studies, a promising interventional strategy for the disease. This prospective clinical study describes the translation of this cellular intervention strategy to patients with recent-onset type 1 diabetes. Twenty adult patients with newly diagnosed type 1 diabetes were enrolled and randomized to MSC treatment or to the control group. Residual beta-cell function was analyzed as C-peptide concentrations in blood in response to a mixed-meal tolerance test (MMTT) at 1-year follow-up. In contrast to the patients in the control arm, who showed loss in both C-peptide peak values and C-peptide when calculated as area under the curve during the 1st year, these responses were preserved or even increased in the MSC-treated patients. Importantly, no side effects of MSC treatment were observed. We conclude that autologous MSC treatment in new-onset type 1 diabetes constitutes a safe and promising strategy to intervene in disease progression and preserve beta-cell function.

Place, publisher, year, edition, pages
American Diabetes Association , 2015. Vol. 64, no 2, 587-592 p.
National Category
Endocrinology and Diabetes
Identifiers
URN: urn:nbn:se:oru:diva-56336DOI: 10.2337/db14-0656ISI: 000348827100026PubMedID: 25204974OAI: oai:DiVA.org:oru-56336DiVA: diva2:1081675
Available from: 2017-03-14 Created: 2017-03-14 Last updated: 2017-03-14Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Schwarcz, Erik
By organisation
Orebro University Hospital
In the same journal
Diabetes
Endocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf